Our expertise in downstream purification of enveloped viral vectors ensures the preservation of maximal product potency and efficacy throughout the manufacturing process.

Genevoyager Proprietary Patent: High-Efficiency, T Cell-Specific Lentiviral Envelope

Improved HEK293 Production System for Lentiviral Vector Scale-up Manufacturing

By systematically optimizing key process parameters — such as transfection reagents, feeding strategies, DNA input ratios, and packaging plasmid ratios — the optimal packaging conditions were established, increasing the infectious titer in the supernatant to 2×108  TU/mL, representing more than a threefold improvement compared with pre-optimization levels.

Through systematic optimization of key parameters—including protectant screening, sample concentration processes, selection of membrane materials and molecular weight cut-off, and overall process control—final lentiviral recovery reached 25.44% for physical titer and 30.37% for infectious titer.

● Four-/five-plasmid transient transfection HEK293 cell systems, including Genevoyager’s optimized production platform
● Client-supplied cell lines

● High viral titers in harvest supernatant
● Processes readily scalable
● Animal component–free raw materials
● Cost-effective production

● Effective removal of impurities such as HCP and HCD
● Maximized viral infectivity
● Simple and robust operations
● Easily scalable in a linear manner
● Reduced overall cost

● Stirred-tank bioreactors (5 L, 10 L, 50 L, 200 L)

● Designed and operated in accordance with BSL-2 requirements
● Manufacturing suites designed and constructed in compliance with FDA, EMA, and NMPA GMP standards, featuring unidirectional flow and independent HVAC systems